A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer

被引:84
作者
Bria, Emilio [1 ]
Milella, Michele [1 ]
Sperduti, Isabella
Alessandrini, Gabriele
Visca, Paolo
Corzani, Felicita
Giannarelli, Diana
Cerasoli, Virna
Cuppone, Federica [1 ]
Cecere, Fabiana Letizia [1 ]
Marchetti, Antonio [2 ]
Sacco, Rocco [3 ]
Mucilli, Felice [3 ]
Malatesta, Sara [2 ]
Guetti, Luigi [3 ]
Vitale, Luca [3 ]
Ceribelli, Anna [1 ]
Rinaldi, Massimo [1 ]
Terzoli, Edmondo [1 ]
Cognetti, Francesco [1 ]
Facciolo, Francesco
机构
[1] Regina Elena Inst Canc Res, Dept Med Oncol, I-00144 Rome, Italy
[2] Univ Fdn, Ctr Excellence Aging, Clin Res Ctr, Chieti, Italy
[3] Univ G dAnnunzio, Dept Surg, Chieti, Italy
关键词
Lymph-nodes; Lung cancer; Prognosis; Early-stage; Classification; Survival; Surgery; VINORELBINE PLUS CISPLATIN; FORTHCOMING 7TH EDITION; STAGE-I; TNM CLASSIFICATION; PROPOSALS; REVISION; PROJECT;
D O I
10.1016/j.lungcan.2009.02.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The number of resected lymph-nodes (#RNs) has proven prognostic in breast and colorectal cancer. Here we evaluated its prognostic impact in a series of resected NSCLC patients. Methods: A panel of established prognostic factors plus (1) #RNs or (2) the ratio between the number of metastatic nodes and #RNs (NR) were correlated to overall- (OS), cancer-specific- (CSS), and disease-free-survival (DFS), using the Cox-model. Risk-classes according to hazard ratios (HR) were generated. Internal and external validation was accomplished. Results: A dataset of 415 resected NSCLC patients was retrieved. At multivariate analysis, #RNs and NR were independent factor for longer OS, CSS and DFS (p<0.0001). Patients with a #RNs> 10 (identified optimal cut-off) had a statistically significant CS (p = 0.02) and DFS (p = 0.0005) benefit. In node-positive patients, a NR < 9% significantly correlated with better outcome. Stratification into High-, Medium-, and Low-Risk classes, based on High- (HRFs: stage, N-status, age, #RNs) and Intermediate-Risk Factors (IRFs: sex, grading, histology), efficiently predicted outcomes (p < 0.0001). The risk class model performance was externally validated in and independent dataset of 297 patients. Conclusions: These results contribute to complete the panel of prognostic factors for resected NSCLC. A prospective larger validation and comparison with molecular prognostic tools is warranted. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 32 条
  • [1] [Anonymous], NCCN CLIN PRACT GUID
  • [2] A Japanese lung cancer registry study - Prognosis of 13,010 resected lung cancers
    Asamura, Hisao
    Goya, Tomoyuki
    Koshiishi, Yoshihiko
    Sohara, Yasunori
    Eguchi, Kenji
    Mori, Masaki
    Nakanishi, Yohichi
    Tsuchiya, Ryosuke
    Shimokata, Kaoru
    Inoue, Hiroshi
    Nitkiwa, Toshihiro
    Miyaoka, Etsuo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) : 46 - 52
  • [3] Survival prediction of stage I lung adenocarcinomas by expression of 10 genes
    Bianchi, Fabrizio
    Nuciforo, Paolo
    Vecchi, Manuela
    Bernard, Loris
    Tizzoni, Laura
    Marchetti, Antonio
    Buttitta, Fiarnma
    Felicioni, Lara
    Nicassio, Francesco
    Di Fiore, Pier Paolo
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (11) : 3436 - 3444
  • [4] CAHAN WG, 1951, J THORAC SURG, V22, P449
  • [5] A five-gene signature and clinical outcome in non-small-cell lung cancer
    Chen, Hsuan-Yu
    Yu, Sung-Liang
    Chen, Chun-Houh
    Chang, Gee-Chen
    Chen, Chih-Yi
    Yuan, Ang
    Cheng, Chiou-Ling
    Wang, Chien-Hsun
    Terng, Harn-Jing
    Kao, Shu-Fang
    Chan, Wing-Kai
    Li, Han-Ni
    Liu, Chun-Chi
    Singh, Sher
    Chen, Wei J.
    Chen, Jeremy J. W.
    Yang, Pan-Chyr
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (01) : 11 - 20
  • [6] COX DR, 1972, J R STAT SOC B, V34, P187
  • [7] Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial
    Douillard, Jean-Yves
    Rosell, Rafael
    De Lena, Mario
    Carpagnano, Francesco
    Ramlau, Rodryg
    Gonzales-Larriba, Jose Luis
    Grodzki, Tornasz
    Pereira, Jose Rodrigues
    Le Groumellec, Alain
    Lorusso, Vito
    Clary, Claude
    Torres, Antonio J.
    Dahabreh, Jabrail
    Souquet, Pierre-Jean
    Astudillo, Julio
    Fournel, Pierre
    Artal-Cortes, Angel
    Jassem, Jacek
    Koubkova, Leona
    His, Patricia
    Riggi, Marcella
    Hurteloup, Patrick
    [J]. LANCET ONCOLOGY, 2006, 7 (09) : 719 - 727
  • [8] Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
    Efficace, F.
    Bottomley, A.
    Smit, E. F.
    Lianes, P.
    Legrand, C.
    Debruyne, C.
    Schramel, F.
    Smit, H. J.
    Gaafar, R.
    Biesma, B.
    Manegold, C.
    Coens, C.
    Giaccone, G.
    Van Meerbeeck, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (11) : 1698 - 1704
  • [9] Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer
    Gajra, A
    Newman, N
    Gamble, GP
    Kohman, LJ
    Graziano, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 1029 - 1034
  • [10] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714